Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The price of BioXcel Therapeutics Inc (NASDAQ: BTAI) closed at $1.71 in the last session, down -1.16% from day before closing price of $1.73. In other words, the price has decreased by -$1.16 from its previous closing price. On the day, 0.31 million shares were traded. BTAI stock price reached its highest trading level at $1.73 during the session, while it also had its lowest trading level at $1.6646.
Ratios:
We take a closer look at BTAI’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 1.16 and its Current Ratio is at 1.17.
Upgrades & Downgrades
In the most recent recommendation for the company, UBS on February 21, 2024, Downgraded its rating to Neutral and sets its target price to $4 from $9 previously.
On August 15, 2023, Mizuho Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $40 to $4.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, BTAI now has a Market Capitalization of 37396832 and an Enterprise Value of 110506832. For the stock, the TTM Price-to-Sale (P/S) ratio is 49.86. Its current Enterprise Value per Revenue stands at 146.951 whereas that against EBITDA is -2.204.
Stock Price History:
The Beta on a monthly basis for BTAI is 0.19, which has changed by -0.7093414 over the last 52 weeks, in comparison to a change of 0.14446163 over the same period for the S&P500. Over the past 52 weeks, BTAI has reached a high of $9.26, while it has fallen to a 52-week low of $1.17. The 50-Day Moving Average of the stock is -14.22%, while the 200-Day Moving Average is calculated to be -25.90%.
Shares Statistics:
According to the various share statistics, BTAI traded on average about 785.27K shares per day over the past 3-months and 449600 shares per day over the past 10 days. A total of 21.87M shares are outstanding, with a floating share count of 21.02M. Insiders hold about 3.89% of the company’s shares, while institutions hold 10.78% stake in the company. Shares short for BTAI as of 1764288000 were 909508 with a Short Ratio of 1.25, compared to 1761868800 on 1402142. Therefore, it implies a Short% of Shares Outstanding of 909508 and a Short% of Float of 4.2700000000000005.
Earnings Estimates
Current recommendations for the stock of the company come from 2.0 analysts. The consensus estimate for the next quarter is -$0.72, with high estimates of -$0.59 and low estimates of -$0.83.
Analysts are recommending an EPS of between -$6.2 and -$7.53 for the fiscal current year, implying an average EPS of -$6.78. EPS for the following year is -$3.05, with 4.0 analysts recommending between -$2.07 and -$4.24.
Revenue Estimates
According to 3 analysts,. The current quarter’s revenue is expected to be $166.67k. It ranges from a high estimate of $200k to a low estimate of $100k. As of. The current estimate, BioXcel Therapeutics Inc’s year-ago sales were $366kFor the next quarter, 3 analysts are estimating revenue of $366.67k. There is a high estimate of $700k for the next quarter, whereas the lowest estimate is $100k.
A total of 3 analysts have provided revenue estimates for BTAI’s current fiscal year. The highest revenue estimate was $600k, while the lowest revenue estimate was $500k, resulting in an average revenue estimate of $554.03k. In the same quarter a year ago, actual revenue was $2.27MBased on 4 analysts’ estimates, the company’s revenue will be $2.86M in the next fiscal year. The high estimate is $6.08M and the low estimate is $400k.
